A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas.

Julie I KrystalDerek HansonDanielle DonnellyMark Atlas

Published in: Pediatric blood & cancer (2024)

Mebendazole was safe and well tolerated when administered with bevacizumab and irinotecan at doses up to 200 mg/kg/day. Further studies are needed to determine the efficacy of this treatment.

Keyphrases

high grade
low grade
metastatic colorectal cancer
open label
clinical trial
case control